ROIVANT SCIENCES LTD
ROIV · NASDAQ
Updated at 2026-10-13 13:57:33
- Today's High
- $34.92
- Today’s Low
- $34.11
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $34.92
- Previous Close
- $34.59
- Volume
- 4.73M
- Market Cap
- $24.98B
- P/E Ratio
- --
- EPS
- $-0.38
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 50 BROADWAY, LONDON, UNITED KINGDOM, SW1H 0DB
- Country
- GB
- Listing Date
- 2020-12-03
- Fiscal Year End
- March
- Shares Outstanding
- 722.41M
- CIK
- 0001635088
- Website
- roivant.com
Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive business model that leverages cutting-edge technologies. The company has developed a promising pipeline addressing critical unmet medical needs in neurology, immunology, and rare diseases, which positions it well to streamline the drug development process while managing costs effectively. With a leadership team rich in industry experience and a network of strategic partnerships, Roivant is poised to drive financial growth and improve patient outcomes, making it an attractive investment opportunity for institutional investors.
Financial Metrics
Revenue
2026-06-30
$1.44M
2026-03-31
$2.52M
2025-12-31
$1.99M
2025-09-30
$1.57M
Operating Expenses
2026-06-30
$367.15M
2026-03-31
$357.19M
2025-12-31
$340.45M
2025-09-30
$307.69M
Net Income
2026-06-30
-$189.83M
2026-03-31
$302.99M
2025-12-31
-$265.89M
2025-09-30
-$113.51M
Net Profit Margin
2026-06-30
-13.16K%
2026-03-31
12.02K%
2025-12-31
-13.3K%
2025-09-30
-7.22K%
Earnings Per Share
2026-06-30
$-0.45
2026-03-31
$-0.32
2025-12-31
$-0.24
2025-09-30
$-0.28
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$293.96M
2026-03-31
$454.73M
2025-12-31
-$289.67M
2025-09-30
-$158.12M
Effective Tax Rate
2026-06-30
1.34%
2026-03-31
21.65%
2025-12-31
-8.03%
2025-09-30
-4.39%
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $1.44M | $2.52M | $1.99M | $1.57M |
| Operating Expenses | $367.15M | $357.19M | $340.45M | $307.69M |
| Net Income | -$189.83M | $302.99M | -$265.89M | -$113.51M |
| Net Profit Margin | -13.16K% | 12.02K% | -13.3K% | -7.22K% |
| Earnings Per Share | $-0.45 | $-0.32 | $-0.24 | $-0.28 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$293.96M | $454.73M | -$289.67M | -$158.12M |
| Effective Tax Rate | 1.34% | 21.65% | -8.03% | -4.39% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.